First Time Loading...

Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 0.43 CAD -3.37% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

EDT Price Targets Summary
Spectral Medical Inc

Wall Street analysts forecast EDT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EDT is 1.84 CAD with a low forecast of 1.82 CAD and a high forecast of 1.89 CAD.

EDT Lowest Forecast
Wall Street Target
1.82 CAD
323% Upside
EDT Average Forecast
Wall Street Target
1.84 CAD
327% Upside
EDT Highest Forecast
Wall Street Target
1.89 CAD
340% Upside
Lowest
Price Target
1.82 CAD
323% Upside
Average
Price Target
1.84 CAD
327% Upside
Highest
Price Target
1.89 CAD
340% Upside
Spectral Medical Inc Competitors:
Price Targets
AURA
Aura Biosciences Inc
156% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
33% Upside
9926
Akeso Inc
26% Upside
P
000403
Pacific Shuanglin Bio pharmacy Co Ltd
10% Downside
AURA
Aura Biosciences Inc
156% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
33% Upside
9926
Akeso Inc
26% Upside
P
000403
Pacific Shuanglin Bio pharmacy Co Ltd
10% Downside
ADAG
Adagene Inc
408% Upside
ADMA
ADMA Biologics Inc
25% Upside
HARP
Harpoon Therapeutics Inc
8% Upside
005690
Pharmicell Co Ltd
201% Upside

Revenue
Forecast

Revenue Estimate
Spectral Medical Inc

For the last 8 years the compound annual growth rate for Spectral Medical Inc's revenue is -8%. The projected CAGR for the next 2 years is 26%.

-8%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Spectral Medical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Spectral Medical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

See Also

Summary
EDT intrinsic value, competitors valuation, and company profile.
DCF Valuation
EDT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EDT stock valuation using valuation multiples.
Wall Street Estimates
EDT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EDT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EDT's stock price target?
Price Target
1.84 CAD

According to Wall Street analysts, the average 1-year price target for EDT is 1.84 CAD with a low forecast of 1.82 CAD and a high forecast of 1.89 CAD.

What is Spectral Medical Inc's Revenue forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Spectral Medical Inc's revenue is -8%. The projected CAGR for the next 2 years is 26%.

ALPHA SPREAD
Join more than 134,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.